Pfizer (PFE) announced updated study results, which confirmed the robust efficacy of its experimental oral antiviral COVID treatment - PAXLOVID - in reducing the risk of hospitalization or death.
According to the announcement, the final data confirmed the results of the interim study showing PAXLOVID reduced the risk of hospitalization or death by 89% in high-risk patients, when used within three days of the appearance of symptoms, and by 88% within five days of the appearance of symptoms.
However, the interim results of the continuing second study in adults at standard risk of developing COVID-19 complications showed a 70% reduction in hospitalization and no deaths.